A New Way to Build Cyclic Peptides That Selectively Target Melanocortin Receptors

The researchers developed and validated a macrocyclization method using nucleophilic aromatic substitution (SNAr) to form thioether bridges in peptides. They tested the approach both in solution with unprotected peptidomimetics and on solid-phase resin with protected peptides. The resulting cyclic peptides were evaluated for binding and activation at melanocortin receptors, generating a library with varying subtype selectivity profiles.

Melanocortin receptors control critical functions including appetite, sexual function, skin pigmentation, and inflammation. Drugs like bremelanotide (Vyleesi) and setmelanotide already target this system. But creating selective melanocortin agonists — ones that activate specific receptor subtypes without triggering unwanted effects — has been a major challenge. This new cyclization method allows rapid generation of diverse cyclic peptide libraries, accelerating the discovery of more selective and potent melanocortin drugs.

Cyclic peptides are one of the most promising drug formats in pharmaceutical development — more stable than linear peptides, more selective than small molecules, and cheaper to make than antibodies. This macrocyclization method adds a new tool to the medicinal chemist's toolkit that could accelerate discovery across many peptide drug programs, not just melanocortin. The melanocortin application is particularly timely given the growing interest in this receptor family for obesity, sexual dysfunction, and rare genetic conditions.

This is a chemistry/drug design study — no animal or human testing. The potency and selectivity were assessed in receptor binding assays only, not in vivo. Whether these cyclic peptides would be bioavailable, stable in the body, or therapeutically useful requires further preclinical and clinical testing. The library approach generates many candidates but doesn't guarantee any will become drugs.